BR0115511A - Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo - Google Patents

Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo

Info

Publication number
BR0115511A
BR0115511A BR0115511-3A BR0115511A BR0115511A BR 0115511 A BR0115511 A BR 0115511A BR 0115511 A BR0115511 A BR 0115511A BR 0115511 A BR0115511 A BR 0115511A
Authority
BR
Brazil
Prior art keywords
apo
elevating
heterozygous familial
reducing
methylsulfonyl
Prior art date
Application number
BR0115511-3A
Other languages
English (en)
Inventor
Ali Raza
Howard Gerard Hutchinson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0115511(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR0115511A publication Critical patent/BR0115511A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODOS PARA TRATAR HIPERCOLESTEROLEMIA FAMILIAR HETEROZIGóTICA, E PARA REDUZIR LDL-C, ELEVAR HDL-C, REDUZIR APO B E ELEVAR APO A-1 EM UM PACIENTE QUE SOFRE DE HIPERCOLESTEROLEMIA FAMILIAR HETEROZIGóTICA, E, USO DE áCIDO (E)-7-[4-(4-FLUOROFENI)-6-ISOPROPIL-2-[METIL (METILSULFONIL) AMINO] PIRIMIDIN-5-IL] (3R,5S)-3,5-DI-HIDROXIHEPT-6-ENóICO OU DE UM SAL FARMACEUTICAMENTE ACEITáVEL DO MESMO". A invenção fornece um método para o tratamento de hipercolesterolemia familiar heterozigótica por administração do composto ácido (E)-7-[4-(4-fluorofeni)-6-isopropil-2-[metil (metilsulfonil) amino] pirimidin-5-il] (3R,5S)-3,5-di-hidroxihept-6-enóico ou de um sal farmaceuticamente aceitável do mesmo.
BR0115511-3A 2000-11-22 2001-11-16 Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo BR0115511A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
BR0115511A true BR0115511A (pt) 2003-12-30

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0115511-3A BR0115511A (pt) 2000-11-22 2001-11-16 Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo

Country Status (35)

Country Link
US (1) US6858618B2 (pt)
EP (1) EP1339409B1 (pt)
JP (2) JP5062940B2 (pt)
KR (1) KR100815042B1 (pt)
CN (1) CN1268339C (pt)
AR (1) AR031766A1 (pt)
AT (1) ATE394103T1 (pt)
AU (2) AU2002214165B9 (pt)
BG (1) BG66009B1 (pt)
BR (1) BR0115511A (pt)
CA (1) CA2429263C (pt)
CY (1) CY1110428T1 (pt)
CZ (1) CZ301583B6 (pt)
DE (1) DE60133921D1 (pt)
DK (1) DK1339409T3 (pt)
EE (1) EE05507B1 (pt)
ES (1) ES2305118T3 (pt)
GB (1) GB0028429D0 (pt)
HK (1) HK1056691A1 (pt)
HU (1) HUP0301380A3 (pt)
IL (2) IL155919A0 (pt)
IS (1) IS6819A (pt)
MX (1) MXPA03004336A (pt)
MY (1) MY134902A (pt)
NO (1) NO326245B1 (pt)
NZ (1) NZ525754A (pt)
PL (1) PL365386A1 (pt)
PT (1) PT1339409E (pt)
RU (1) RU2294744C2 (pt)
SI (1) SI1339409T1 (pt)
SK (1) SK6212003A3 (pt)
TW (1) TWI238720B (pt)
UA (1) UA75614C2 (pt)
WO (1) WO2002041895A1 (pt)
ZA (1) ZA200303636B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EA200501676A1 (ru) * 2003-04-25 2006-04-28 Джилид Сайэнс, Инк. Фосфонатсодержащие ингибиторы киназы (варианты), способ их получения, фармацевтическая композиция, лекарственная форма на их основе и способ ингибирования киназы у млекопитающего (варианты)
ATE490788T1 (de) * 2003-04-25 2010-12-15 Gilead Sciences Inc Antivirale phosphonate analoge
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
US7244844B2 (en) * 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
AU2005247160A1 (en) * 2004-05-26 2005-12-08 Kgk Synergize Inc Functional foods comprising flavonoids and tocotrienols and methods thereof
CA2573857A1 (en) * 2004-07-13 2006-02-16 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
EP1778251B1 (en) 2004-07-27 2011-04-13 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
KR100945763B1 (ko) 2005-02-22 2010-03-08 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴의 제조 방법
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
TW200800917A (en) * 2005-08-16 2008-01-01 Teva Pharma Crystalline rosuvastatin intermediate
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
CA2725052C (en) 2008-05-27 2014-09-16 Changzhou Pharmaceutical Factory Co., Ltd. Preparation method of rosuvastatin calcium and its intermediates
AU2009268681B2 (en) 2008-07-08 2014-10-02 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
EP3689853B1 (en) 2012-09-17 2021-11-24 Madrigal Pharmaceuticals, Inc. Method of synthesizing thyroid hormone analogs and polymorphs thereof
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
EA202193139A1 (ru) 2019-05-27 2022-03-01 Имматикс Юс, Инк. Вирусные векторы и их применение в адоптивной клеточной терапии
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
AU2022213405A1 (en) * 2021-02-01 2023-08-03 Madrigal Pharmaceuticals, Inc. Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
JP2010031047A (ja) 2010-02-12
PL365386A1 (en) 2005-01-10
BG66009B1 (bg) 2010-10-29
IL155919A (en) 2009-09-01
AR031766A1 (es) 2003-10-01
CA2429263C (en) 2009-03-17
DK1339409T3 (da) 2008-09-08
AU1416502A (en) 2002-06-03
HUP0301380A3 (en) 2007-03-28
MXPA03004336A (es) 2003-08-19
AU2002214165B9 (en) 2013-07-04
PT1339409E (pt) 2008-07-07
CN1268339C (zh) 2006-08-09
DE60133921D1 (de) 2008-06-19
BG107811A (bg) 2004-03-31
JP2004522714A (ja) 2004-07-29
CZ301583B6 (cs) 2010-04-21
EE200300239A (et) 2003-08-15
KR100815042B1 (ko) 2008-03-18
ES2305118T3 (es) 2008-11-01
ATE394103T1 (de) 2008-05-15
IL155919A0 (en) 2003-12-23
RU2294744C2 (ru) 2007-03-10
HUP0301380A2 (hu) 2003-10-28
CN1630520A (zh) 2005-06-22
NO20032292D0 (no) 2003-05-21
TWI238720B (en) 2005-09-01
US6858618B2 (en) 2005-02-22
MY134902A (en) 2007-12-31
CY1110428T1 (el) 2015-04-29
EP1339409A1 (en) 2003-09-03
NO20032292L (no) 2003-07-17
JP5062940B2 (ja) 2012-10-31
SK6212003A3 (en) 2003-11-04
US20040072852A1 (en) 2004-04-15
UA75614C2 (uk) 2006-05-15
NZ525754A (en) 2004-10-29
AU2002214165B2 (en) 2006-12-14
GB0028429D0 (en) 2001-01-10
WO2002041895A1 (en) 2002-05-30
HK1056691A1 (en) 2004-02-27
IS6819A (is) 2003-05-19
EE05507B1 (et) 2012-02-15
NO326245B1 (no) 2008-10-27
KR20030048479A (ko) 2003-06-19
EP1339409B1 (en) 2008-05-07
ZA200303636B (en) 2004-08-12
CZ20031406A3 (cs) 2003-09-17
CA2429263A1 (en) 2002-05-30
SI1339409T1 (sl) 2008-08-31

Similar Documents

Publication Publication Date Title
BR0115511A (pt) Métodos para tratar hipercolesterolemia familiar heterozigótica, e para reduzir ldl-c, elevar hdl-c, reduzir apo b e elevar apo a-1 em um paciente que sofre de hipercolesterolemia familiar heterozigótica, e, uso de ácido (e) -7- [4- (4- fluorefenil) -6- isopropil-2- [metil (metilsulfonil) amino] pirimidin -5- il] (3r,5s) - 3,5- di - hidroxihept -6- enóico ou de um sal farmaceuticamente aceitável do mesmo
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
RU2003114300A (ru) Применение розувастатина (zd-4522) в лечении гетерозиготной семейной гиперхолестеринемии
ATE541860T1 (de) Humane antikörper gegen cd40 zur therapie von b- zell tumoren
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
AU7031500A (en) Therapeutic quinazoline compounds
BRPI0513565A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir uma atividade de proteìna cinase, e para tratar um paciente tendo uma condição que é mediada por atividade de proteìna cinase, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, e, composição farmacêutica
IL178748A0 (en) Methods for treatment and management of lung cancers using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
GEP20022693B (en) Pyrimidine Derivatives as HMG-Coa Reductase Inhibitors
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
BR9908510A (pt) Uso de um composto, composto, processo para a preparação de um composto, composição farmacêutica, e, processo de tratar um paciente que sofre de, ou em risco de, uma doença micobacteriana
BR0308957A (pt) Composto, composição farmacêutica, método para o tratamento de uma inflamação ou de uma desordem associada a uma inflamação em um paciente, uso dos compostos e processo para sua preparação
EP1256344A4 (en) REMEDIES FOR ENDOTHELIN-INDUCED DISEASES
BR0007452A (pt) Uso de melagatrano ou de um derivado farmaceuticamente aceitável ou pró-droga do mesmo, método de tratamento de inflamação, e, formulação farmacêutica para uso no tratamento de inflamação
DE69934689D1 (de) Verwendung der protein-kinase-c-epsilon-inhibitoren zur behandlung von schmerzen
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
WO2005058341A3 (en) Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
BR0315140A (pt) Combinação, composição farmacêutica, método de tratamento do câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
MY136382A (en) Use of cholesterol-lowering agent
BR0211358A (pt) Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis
BR9913242A (pt) Uso de r(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-p iperidinametanol para o tratamento de desordens de sono
WO2003072737A3 (en) Biological inhibitions induced by contact inhibitory factor
GT200100066A (es) Agente hipertensivo y su uso.

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO ART. 6O, II, "B" DA RESOLUCAO 191/08.

B65X Notification of requirement for priority examination of patent application
B65Z Priority examination of the patent application refused (request does not comply with dec. 132/06 of 20061117)

Free format text: NEGADO O EXAME PRIORITARIO DO PEDIDO DE PATENTE UMA VEZ QUE NAO FOI ATENDIDO O DISPOSTO NO ART. 6O, II, "B" DA RESOLUCAO 191/08.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.